Cassileth P A, Gale R P
Leuk Res. 1986;10(11):1257-65. doi: 10.1016/0145-2126(86)90331-0.
Amsacrine is an acridine derivative that has been extensively evaluated for its antitumor activity in recent years. Amsacrine is active in the treatment of acute leukemias and lymphomas but largely ineffective in solid tumors. In acute myelogenous leukemia, amsacrine is as effective as the two most active drugs, cytarabine and daunorubicin and can produce complete remissions in patients refractory to these drugs. The addition of amsacrine to the limited therapeutic armamentarium for this disease offers the potential for improved remission rates and remission duration.
安吖啶是一种吖啶衍生物，近年来已对其抗肿瘤活性进行了广泛评估。安吖啶在急性白血病和淋巴瘤的治疗中具有活性，但对实体瘤基本无效。在急性髓性白血病中，安吖啶与两种活性最强的药物阿糖胞苷和柔红霉素效果相当，并且能使对这些药物耐药的患者实现完全缓解。在这种疾病有限的治疗手段中加入安吖啶，有可能提高缓解率并延长缓解期。
